BrosMed Announces Strategic Agreement with Cardinal Health

BrosMed Announces Strategic Agreement with Cardinal Health

March 31st, 2017 in CIT 2017 Beijing China — BrosMed announced that it has entered into a strategic distribution agreement with Cardinal Health.

Through this distribution agreement, BrosMed Medical will significantly increase the market share and penetration of its leading family of percutaneous transluminal coronary angioplasty (PTCA) which includes Artimes™ Semi-Compliant and Apollo™ Non-Compliant coronary balloon dilatation catheters.

The agreement will initially enable Cordis, Cardinal Health’s interventional vascular business, to distribute BrosMed’s brand PTCA balloon dilatation catheter in mainland China. Both Artimes™ and Apollo™ products which have obtained CFDA and CE approval and FDA clearance are manufactured in China and being sold globally.

“The agreement between BrosMed Medical and Cardinal Health is an extremely important milestone in our continuing strategy to deepen our market penetration and expand as well as diversify our products offering and service,” said Benny Lee, Chairman of BrosMed Medical. “Working together with Cardinal Health shall be able to leverage our joint capabilities of delivering state-of-art products including Artimes™ and Apollo™ PTCA, while maximizing the increased market coverage in the Mainland China through geographical footprint of BrosMed Medical and Cordis franchises.”

“Our PTCA portfolio covers semi-compliant, non-compliant and CTO 1.0mm balloon catheters, the products are being sold in thirty (30) countries and territories, including USA , China and EU, those are well received in the market and acknowledged by top key opinion leader (KOL). BrosMed dedicate ourselves to the new products and technology in order to consistently provide high quality products and services to the cardiovascular and endovascular patients around the world.” said Stephen Lee, General Manager of BrosMed Medical.

About BrosMed Medical

BrosMed Medical is more than just a company; we are leading the medical device design and manufacturing revolution. BrosMed Medical develops, manufactures and markets medical devices primarily used by interventional cardiologists, radiologists and vascular surgeons in angioplasty procedures and other minimal invasive devices.

We provide solutions to our customers through innovative design, effective supply chain management, world-class manufacturing, and flexible channels of distribution and through the development or acquisition of innovative technologies.

BrosMed Medical product portfolio consist of, Artimes™ CTO PTCA, Artimes™ PTCA, Apollo™ NC PTCA, Atropos™ 0.035 PTA, Minerva™ 0.018 PTA, Polux™ 0.014 PTA, Hermes™ NC 0.035 PTA, Achilles™ NC 0.018 PTA, Castor™ NC 0.014 PTA, Conger™ Hydrophilic coated wire and FreepathTM Catheter Sheath Introducer. BrosMed Medical is supplying safe, effective and hi-tech medical devices in 30 countries.

About Cardinal Health

Cardinal Health, Inc. (NYSE: CAH), is a global integrated healthcare services and products company, providing customized solutions for hospital systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company provides clinically-proven medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. Cardinal Health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. Backed by nearly 100 years of experience, with more than 37,000 employees in nearly 60 countries, Cardinal Health ranks among the top 25 on the Fortune 500.

Cordis is a worldwide leader in the development and manufacture of interventional vascular technology with a more than 50-year history of delivering pioneering products to treat millions of patients. With a reputation for clinical acumen, training and services, Cordis established a legacy of innovation in high-quality and less-invasive cardiovascular products and built a strong global footprint with operations in countries around the world.

As of October 2015, Cordis is a part of Cardinal Health, bringing together two important players in the healthcare industry and creating an unmatched combined offering in the cardiovascular space that will ensure greater access to quality products and services worldwide.